SAN ANTONIO and SAN CARLOS, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Nektar
Therapeutics (Nasdaq: NKTR) presented clinical study data today demonstrating
that the oral tablet formulation of NKTR-118 has favorable systemic
bioavailability and a low risk for mediating significant drug-drug
interactions. NKTR-118, an oral peripherally-acting opioid antagonist, is in
clinical development for the treatment of opioid-induced constipation. These
findings were presented today at the 38th Annual American College of Clinical
Pharmacology (ACCP) Meeting in San Antonio, Texas.
